Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 2.370% | 5.620% | 4.583% | 24.380% | -9.265% | -18.077% | -39.114% |
| Opko Health Inc. | 1.800% | 6.604% | -10.317% | 8.321% | 3.651% | -31.140% | -61.235% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 0.580% | 0.000% | 6.135% | -12.626% | -11.735% | -33.462% | -24.123% |
Comments
News
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
Stanley Druckenmiller isn't afraid to take risks. His boldness has paid off through the years. Druckenmiller's net worth stands at $7.8 billion. His Duquesne Family Office has roughly $3 billion in
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amneal reported strong Q2 results, with revenue up 10% to $796 million, adjusted EBITDA up 12% to
